

## MOTS-c(human) acetate

<b>Cat. No.:</b>	HY-P2048A		
<b>Molecular Formula:</b>	C <sub>103</sub> H <sub>156</sub> N <sub>28</sub> O <sub>24</sub> S <sub>2</sub>		
<b>Molecular Weight:</b>	2234.64		
<b>Sequence:</b>	Met-Arg-Trp-Gln-Glu-Met-Gly-Tyr-Ile-Phe-Tyr-Pro-Arg-Lys-Leu-Arg	MRWQEMGYIFYPRKLR (acetate salt)	
<b>Sequence Shortening:</b>	MRWQEMGYIFYPRKLR		
<b>Target:</b>	AMPK; GLUT		
<b>Pathway:</b>	Epigenetics; PI3K/Akt/mTOR; Membrane Transporter/Ion Channel		
<b>Storage:</b>	Sealed storage, away from moisture		
	Powder	-80°C	2 years
		-20°C	1 year
	* In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)		

### SOLVENT & SOLUBILITY

#### In Vitro

DMSO : 4 mg/mL (1.79 mM; Need ultrasonic)

Preparing Stock Solutions	Solvent Concentration	Mass	1 mg	5 mg	10 mg
	1 mM		0.4475 mL	2.2375 mL	4.4750 mL
	5 mM		---	---	---
	10 mM		---	---	---

Please refer to the solubility information to select the appropriate solvent.

### BIOLOGICAL ACTIVITY

#### Description

MOTS-c(human) acetate is a mitochondrial-derived peptide. MOTS-c(human) acetate induces the accumulation of AMP analog AICAR, increases activation of AMPK and expression of its downstream GLUT4. MOTS-c(human) acetate induces glucose uptake and improves insulin sensitivity. MOTS-c(human) acetate has implications in the regulation of obesity, diabetes, exercise, and longevity<sup>[1]</sup>.

#### IC<sub>50</sub> & Target

AMPK	GLUT4	AICAR
------	-------	-------

#### In Vitro

MOTS-c inhibits the folate cycle at the level of 5Me-THF, resulting in an accumulation of AICAR [5-aminoimidazole-4-carboxamide ribonucleotide). MOTS-c also increases cellular NAD<sup>+</sup> levels, which are also nucleotide precursors<sup>[1]</sup>. MOTS-c is a mitochondrial signal that stimulates cellular glucose uptake while suppressing respiration. The glucose taken up in response to MOTS-c is routed to the anabolic pentose phosphate pathway (PPP), which provides carbon sources for the synthesis of purines, rather than being metabolized through glycolysis. In addition, MOTS-c increases the levels of carnitine shuttles, which transport activated fatty acids into the mitochondria for β-oxidation, increases the level of a β-oxidation intermediate, and reduces intracellular levels of essential and non-essential fatty acids, suggesting enhanced lipid

---

utilization; myocytes that stably overexpress MOTS-c also exhibits increased glucose uptake<sup>[1]</sup>.  
MCE has not independently confirmed the accuracy of these methods. They are for reference only.

**In Vivo**

MOTS-c injections in mice show activation of skeletal muscle AMPK and increased the level of its downstream glucose transporter GLUT4. MOTS-c may also act as a potential mitochondrial signal that mediates an exercise-induced mitohormesis response, thereby stimulating physiological adaptation and increased tolerance to exercise<sup>[1]</sup>.  
The primary target organ of MOTS-c appears to be skeletal muscle and fat. MOTS-c levels in mice decline with age in skeletal muscle and in circulation concomitantly with the age-dependent development of insulin resistance. Restoring MOTS-c levels by systemic injections in older mice (12 mo.) successfully reverses age-dependent skeletal muscle insulin resistance<sup>[1]</sup>.  
MCE has not independently confirmed the accuracy of these methods. They are for reference only.

---

## REFERENCES

[1]. Changhan Lee, et al. MOTS-c: A Novel Mitochondrial-Derived Peptide Regulating Muscle and Fat Metabolism. Free Radic Biol Med. 2016 Nov;100:182-187.

---

**Caution: Product has not been fully validated for medical applications. For research use only.**

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA